Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions

Chronic Hepatitis C

Interventions

DRUG

ANZ-521

3x10\^7 cfu or 3x10\^8 cfu ANZ-521 in 250 mL, IV over 2 hours, every 28 days for up to 3 doses.

DRUG

Placebo

250 mL normal saline, IV over 2 hours, every 28 days for up to 3 doses.

Trial Locations (2)

Alamo Medical Research, San Antonio

Advanced Clinical Research Institute, Anaheim